| HOME >> BIOLOGY >> TECHNOLOGY |
AURORA, Ontario, Sept. 30 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced that it has received subscriptions for the purchase, by way of private placement, of a total of 6,800,000 units at $1.68 per unit, for gross proceeds totaling CDN$11,424,000. The Company anticipates closing the private placement within the next ten days.
Each unit consists of one common share and one-half of one common share purchase warrant, with each whole common share purchase warrant entitling the holder to purchase one common share at a price of $2.36 for up to three years after the closing date of the private placement.
"This is an exciting time for Helix as we open clinical trial sites in Germany for our trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts, prepare for additional clinical trials for this treatment and continue to progress towards clinical testing with L-DOS47," said John Docherty, president of Helix BioPharma. "We plan to use the proceeds from the placement for working capital, primarily to support these research and development initiatives."
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in
the field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its
proprietary technologies. Helix's product development initiatives include
its Topical Interferon Alpha- 2b and its novel L-DOS47 new drug candidate.
Helix is listed on the TSX under the symbol "HBP".
For further information contact:
Investor & Media Relations
Ian Stone
Russo Partners LLC
Tel: (619) 814-3510
Fax: (619) 955-5318
Email: ian.stone@russopartnersllc.com
David Schull
Russo Partners LLC
Tel: (212) 845-4271
Email: david.schull@ru
'/>"/>
| SOURCE Helix BioPharma Corp. Copyright©2008 PR Newswire. All rights reserved |